07.03.2013 09:20 Uhr, Quelle: Wallstreet online

AmVac´s Vaccine Against RSV Attains Next Milestone

ZUG, Switzerland, March 7, 2013 /PRNewswire/ AmVac AG announces new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate …

Weiterlesen bei Wallstreet online

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz